Germany Netherlands Medical Marijuana Market: Market Size & Forecast 2026

The Germany-Netherlands medical marijuana market is positioned at the forefront of Europe's medicinal cannabis industry, driven by progressive regulatory frameworks and significant patient demand. Germany's medical cannabis program, which formally liberalized access in 2017, has rapidly expanded into a market exceeding 670 million in estimated value, with overall cannabis-related sales surpassing 1 billion in 2025. The Netherlands, leveraging its longstanding tolerance-based cannabis policies and official government-sanctioned medical cannabis production through the Bureau voor Medicinale Cannabis, provides a complementary market with distinct supply chain characteristics.

• •Market valued at approximately $1.09 billion in 2025 across Germany and the Netherlands combined
• •Germany dominates regional market share with pharmacy-based distribution exceeding 1 billion in sales
• •Projected to reach $1.3 billion by 2033, reflecting sustained expansion across both countries

The market's robust 13.0% annual growth rate reflects converging regulatory, social, and economic factors across both nations. Germany's ongoing cannabis legalization process, including the anticipated establishment of regulated adult-use markets alongside expanded medical access, has significantly increased investor confidence and industry participation. The substantial import volumes underscore Germany's current reliance on international supply chains, particularly from Canada, Portugal, Denmark, and Australia, creating both growth opportunities and import-dependency challenges that domestic cultivation initiatives aim to address.

• •Regulatory liberalization in Germany, including the 2024 Cannabis Act and planned legal adult-use framework, expanding market access and legitimacy
• •Growing physician prescribing rates and patient acceptance of cannabis-based medicines for chronic conditions
• •Government-backed import dependency creating opportunities for domestic cultivation and supply chain development

The market spans two primary product categories dried cannabis flower and cannabis-derived oils both distributed through Germany's pharmacy network, with oils and pharmaceutical preparations representing a growing share due to standardization and dosing precision. Application segments center on chronic pain management, neurological and mental health disorders, and oncology-related symptom treatment. Germany accounts for the overwhelming majority of regional market value, with its 201-tonne import requirement highlighting massive supply needs, while the Netherlands contributes through its tightly controlled but internationally recognized medical cannabis supply program.

• •Primary product segments: dried cannabis flower and pharmaceutical-grade cannabis oil/extracts
• •Key therapeutic applications: chronic pain, mental disorders, and cancer-related symptoms
• •Germany represents the dominant market with imports of 201 tonnes of medical cannabis in 2025

What are the recent trends and outlook?

The market is transitioning from a supply-constrained import-dependent model toward a more diversified ecosystem that may include domestic German cultivation following regulatory developments. Adult-use legalization discussions in Germany, separate from but complementary to the medical market, are expected to further normalize cannabis access and drive additional professional and public acceptance. Standardization of pharmaceutical-grade products, increasing clinical research, and evolving reimbursement policies from health insurers are anticipated to shape the market's maturation over the coming decade as it approaches projected values of $1.3 billion.

• •Shift toward domestic cultivation in Germany as regulatory frameworks for licensed production develop
• •Growing emphasis on pharmaceutical standardization and clinical evidence to support broader medical adoption
• •Potential cross-pollination between medical and adult-use markets as Germany advances full legalization